Cargando…
Antagonism of CGRP Signaling by Rimegepant at Two Receptors
The “gepants” are a class of calcitonin gene-related peptide (CGRP) receptor antagonist molecules that have been developed for the prevention and treatment of migraine. Rimegepant is reported to act at the CGRP receptor, has good oral bioavailability, and has had positive clinical trial results. How...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468408/ https://www.ncbi.nlm.nih.gov/pubmed/32973499 http://dx.doi.org/10.3389/fphar.2020.01240 |